Valuation: Genome & Company

Market Cap 132B 98.44M 89.65M 82.61M 75.15M 141M 9.12B 148M 1.01B 400M 4.98B 369M 362M 15.62B P/E 2024
-4.17x
P/E 2025 -33.5x
Enterprise Value 114B 85.12M 77.53M 71.44M 64.98M 122M 7.88B 128M 869M 346M 4.31B 319M 313M 13.51B EV / Sales 2024
1.31x
EV / Sales 2025 8.97x
Free-Float
85.67%
Yield 2024 *
-
Yield 2025 -
Sep. 20 Genome & Company(KOSDAQ:A314130) added to S&P Global BMI Index CI
Aug. 14 Genome & Company Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
Apr. 13 Genome & Company announced that it has received KRW 6.99999414 billion in funding CI
Apr. 02 Genome & Company announced that it expects to receive KRW 6.99999414 billion in funding CI
Mar. 12 Genome & Company announced that it has received KRW 29.99998254 billion in funding from DongKoo Bio & Pharma Co., Ltd. CI
25-09-21 Genome & Company(KOSDAQ:A314130) dropped from S&P Global BMI Index CI
25-08-20 An undisclosed buyer agreed to acquire 40.12% stake in List Biotherapeutics, Inc. from Genome & Company for $19.1 million. CI
25-07-10 Genome & Company announced that it has received KRW 25.7890592 billion in funding CI
25-04-27 Genome & Company announced that it has received KRW 27.066097613 billion in funding from a group of investors CI
25-04-23 Genome & Company announced that it expects to receive KRW 27.066097613 billion in funding from a group of investors CI
25-04-23 Genome & Company announced that it expects to receive KRW 27.06426965 billion in funding CI
25-04-23 Genome & Company agreed to acquire an additional 28.64% stake in List Biotherapeutics, Inc. from a group of shareholders for KRW 27.07 billion. CI
24-07-18 Genome & Company announced that it has received KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd. CI
1 day-11.25%
1 week-19.84%
Current month-27.96%
1 month-40.17%
3 months-39.95%
6 months-51.44%
Current year-63.30%
1 week 2,450
Extreme 2450.00000000
3,275
1 month 2,450
Extreme 2450.00000000
4,160
Current year 2,450
Extreme 2450.00000000
10,180
1 year 2,450
Extreme 2450.00000000
10,180
3 years 2,170
Extreme 2170
10,180
5 years 2,170
Extreme 2170
20,000
10 years 2,170
Extreme 2170
47,500
Manager TitleAgeSince
Chief Executive Officer 53 2015-09-23
Chief Executive Officer 55 2015-09-23
Director TitleAgeSince
Director/Board Member 55 2015-09-23
Director/Board Member 53 2015-09-23
Director/Board Member 62 -
Date Insider Type Main position Quantity % Market Cap. Importance
5/9/25 Don

Chief Executive Officer

100,000 0.3217%
5/9/25 Free

Director

40,000 0.1287%
5/9/25 Free

Public Communications Manager

50,000 0.1608%
Change 5-day change 1-year change 3-year change Capi.($)
-11.25%-19.84%-13.23%-61.86% 98.44M
-2.49%-3.76%+53.38%+62.10% 63.66B
-0.63%-2.91%+6.55%+89.34% 58.56B
-2.37%-2.22%+21.77%+84.58% 54.19B
-2.19%-6.15%+12.43%+111.40% 44.66B
-1.89%-7.28%+9.30%+18.50% 40.51B
-0.93%-0.47%+19.34%+41.83% 36.27B
+1.11%-6.44%+127.46%+675.37% 34.87B
-0.80%+0.61%+76.27%+61.80% 32.26B
-2.17%+16.65%-28.89%+479.93% 31.01B
Average -2.36%-2.58%+28.44%+156.30% 40B
Weighted average by Cap. -1.48%-1.86%+31.82%+155.09%

Financials

2024 2025
Net sales 27.74B 20.68M 18.84M 17.36M 15.79M 29.62M 1.92B 31.13M 211M 83.96M 1.05B 77.6M 75.96M 3.28B 24.59B 18.33M 16.69M 15.38M 13.99M 26.25M 1.7B 27.59M 187M 74.4M 927M 68.76M 67.31M 2.91B
Net income -20.11B -14.99M -13.65M -12.58M -11.45M -21.47M -1.39B -22.57M -153M -60.86M -758M -56.25M -55.06M -2.38B -6.43B -4.79M -4.36M -4.02M -3.66M -6.86M -444M -7.21M -48.94M -19.45M -242M -17.98M -17.6M -761M
Net Debt -48.91B -36.46M -33.2M -30.59M -27.83M -52.21M -3.38B -54.87M -372M -148M -1.84B -137M -134M -5.79B -17.86B -13.31M -12.13M -11.17M -10.16M -19.07M -1.23B -20.04M -136M -54.05M -673M -49.96M -48.9M -2.11B
Projected Income Statement - Annual - Genome & Company
Logo Genome & Company
Genome&Company Inc is a Korea-based company primarily engaged in the business of new drug development. The Company operates its business through three segments. The New Drug Development segment primarily develops anticancer drugs and microbiome medicines. The Contract Development and Manufacturing Organization (CDMO) segment primarily provides microbiome therapeutic contract development and manufacturing organization services. The Consumer segment primarily engages in the microbiome cosmetics and health functional food business.
Employees
96
Date Price Change Volume
26-11-20 ₩2,525.00 -11.25% 786,172
26-11-19 ₩2,845.00 -5.17% 348,880
26-11-18 ₩3,000.00 +2.74% 183,441
26-11-17 ₩2,920.00 -1.52% 252,345
26-11-16 ₩2,965.00 -5.87% 540,405
  1. Stock Market
  2. Stocks
  3. A314130 Stock